APA (7th ed.) Citation

NN, S., PL, Z., M, W., SD, N., E, L., Y, O., . . . CY, C. (2025). Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: Phase 1/2 BRUIN study. Blood advances, 9(23), 5954. https://doi.org/10.1182/bloodadvances.2024014975

Chicago Style (17th ed.) Citation

NN, Shah, et al. "Pirtobrutinib, a Highly Selective, Noncovalent (reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study." Blood Advances 9, no. 23 (2025): 5954. https://doi.org/10.1182/bloodadvances.2024014975.

MLA (9th ed.) Citation

NN, Shah, et al. "Pirtobrutinib, a Highly Selective, Noncovalent (reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study." Blood Advances, vol. 9, no. 23, 2025, p. 5954, https://doi.org/10.1182/bloodadvances.2024014975.